Insilico Medicine Launches First-in-Human Trial for AI-Discovered IBD Drug
HIT Consultant
DECEMBER 7, 2023
What You Should Know: Insilico Medicine (“Insilico”) , a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, today announced that the company has initiated the first-in-human study for ISM5411, a potentially first-in-class PHD inhibitor for the treatment of inflammatory bowel disease (IBD). Designed and developed by Insilico’s proprietary end-to-end AI drug discovery platform, Pharma.AI, ISM5411 is Insilico’s fifth AI drug program to enter the c
96 96
Let's personalize your content